Key result
ApoB-specific CD4+ T cells switch between protective regulatory and pathogenic inflammatory states in atherosclerosis.
Why the study?
Substantial residual cardiovascular risk persists despite intensive lipid-lowering therapy, and antigen-specific adaptive immunity directed at ApoB-containing lipoproteins may contribute to the remaining inflammatory burden in atherosclerosis.
Answers are grounded in this paper and cite their sources.
This review highlights that ApoB-specific CD4+ T cells link lipoprotein retention to adaptive autoimmunity in atherosclerosis, shifting from protective regulatory phenotypes to pro-inflammatory states as disease progresses and offering a target for antigen-specific tolerance therapies.
Despite intensive lipid-lowering therapy, substantial residual cardiovascular risk persists, and antigen-specific adaptive immunity may contribute to the inflammatory burden that remains after lipid levels are controlled. Apolipoprotein B (ApoB)-containing lipoproteins accumulate in the arterial wall and undergo local modification. During this process, ApoB-containing material may be taken up by antigen-presenting cells, processed into self-peptides, and presented through MHC-II molecules to CD4 + T cells. This review focuses on ApoB antigen processing and presentation, the functional heterogeneity of ApoB-reactive CD4 + T cells, and emerging antigen-specific therapeutic approaches. Evidence from selected mouse models and human HLA-restricted systems indicates that ApoB-reactive T cells can acquire FoxP3 + regulatory features. However, under hyperlipidemic conditions and during advanced disease, these regulatory features may overlap with, or be replaced by, T-bet + , memory-like, and pro-inflammatory phenotypes. Human studies using HLA-DR-p18 tetramers, activation-induced marker assays in peripheral blood mononuclear cells, and single-cell TCR analyses have begun to define disease-associated differences in ApoB-reactive T-cell states. Even so, current data do not yet prove longitudinal transitions within the same T-cell clones. Interpretation is further limited by HLA restriction, the rarity of ApoB-reactive cells, and relatively small study cohorts. In preclinical models, ApoB peptide vaccination and mucosal tolerance approaches suggest that antigen-specific immunity can be shifted toward regulation without broad immunosuppression. Taken together, ApoB-specific immunity appears to reflect a changing balance between tolerance and inflammation, influenced by antigen burden, HLA background, antigen-presenting cell status, and lesion stage.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2026) conducted a review in Atherosclerosis. ApoB-specific tolerance strategies (e.g., ApoB peptide vaccination, mucosal tolerance) was evaluated. ApoB-specific CD4+ T cells exhibit plasticity between protective FoxP3+ regulatory states and pathogenic T-bet+ inflammatory states during atherosclerosis progression.
Synapse has enriched 10 related papers. Consider them for comparative context: